Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Mutations at S1/S2 site reduce SARS-CoV-2 S cleavage. by Prerna Arora (821926)

Change in per capita growth rate of intraspecies cooperating population implemented with a continuous model. by Yaron Goldberg (10164674)

Effects of soil microorganisms application to substrates of different organic matter content on Quantum Yield (QY) (A) and Normalized Difference Vegetation Index (NDVI) (B) in toma... by Robert Pokluda (8871407)

FTY720 potentiated the activity of cisplatin. by Laura L. Stafman (6577184)

An example of regional-level GIS outputs derived via the questionnaire data: Collated fisher responses to trends in dugong captures in fishing gear across all recorded years, scale... by Nicolas J. Pilcher (203564)

PAM16 correlation with N-MYC. by Zahra Motahari (6814013)

Expression of MAGMAS in medulloblastoma. by Zahra Motahari (6814013)

MAGMAS inhibition on mitochondrial activity in medulloblastoma cells. by Zahra Motahari (6814013)

MAGMAS inhibition induces medulloblastoma cell death. by Zahra Motahari (6814013)

BT9 reduces DAOY and D425 medulloblastoma cell invasion. by Zahra Motahari (6814013)

The effect of MAGMAS inhibition on mitochondrial respiration and acidification rate in D425 cells. by Zahra Motahari (6814013)

MAGMAS inhibition reduces DAOY cells migration. by Zahra Motahari (6814013)

BT9 did not improve survival in the orthotopic xenograft model of D425 medulloblastoma. by Zahra Motahari (6814013)

Experiments were conducted in the operant conditioning box (A, protocols 1–6) or a home cage (B, protocol 6). by Agnieszka D. Wardak (17941139)